Companies: 10,795·Total market cap: $144.5T
Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc.

ACXPNASDAQHealthcare● Active
$1.62
$-0.06(-3.57%)
Market Cap$2567664
P/E Ratio
52W High$21
52W Low$1.326

Acurx Pharmaceuticals, Inc. (ACXP) · Income Statement

Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.

FMP · ACXP · as of 2026-06-08

Financial statements

Revenue · Gross Profit · Net Income
Breakdown2025-122024-122023-122022-122021-12
Revenue
Revenue$0.00B$0.00B$0.00B$0.00B$0.00B
Cost of Revenue$0.00B$0.00B$0.00B$0.00B$0.00B
Gross Profit$0.00B$0.00B$0.00B$0.00B$0.00B
Gross Margin %(computed)
Operating Expenses
R&D Expenses$1.83B$0.01B$0.01B$0.00B$0.00B
G&A Expenses$6.26B$0.01B$0.01B$0.01B$0.01B
Total Operating Expenses$0.01B$0.01B$0.01B$0.01B$0.01B
Operating Income($0.01B)($0.01B)($0.01B)($0.01B)($0.01B)
Operating Margin %(computed)
Interest Income$0.00B$0.00B$0.00B$0.00B$0.00B
Interest Expense$0.00B$0.00B$0.00B$0.00B$0.00B
Income Before Tax($0.01B)($0.01B)($0.01B)($0.01B)($0.01B)
Income Tax Expense$0.00B$0.00B$0.00B$0.00B$0.00B
Net Income($0.01B)($0.01B)($0.01B)($0.01B)($0.01B)
Net Margin %(computed)
Per Share & EBITDA
EPS (Basic)$-5.32$-17.59$-23.01$-22.36$-24.96
Wtd Avg Shares0.00B0.00B0.00B0.00B0.00B
EBITDA($0.01B)$0.00B($0.01B)($0.01B)($0.01B)
EBITDA Margin %(computed)

Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B

Explore more Acurx Pharmaceuticals, Inc. data

About Acurx Pharmaceuticals, Inc. (ACXP) Income Statement

Acurx Pharmaceuticals, Inc. (ACXP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ACXP reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.01B) — a net profit margin of —.

Frequently asked questions

ACXP · 4 questions

Acurx Pharmaceuticals, Inc. (ACXP) reported revenue of $0.00B for 2025, down —% year-over-year.

ACXP revenueACXP salesannual revenue YoYincome statement

· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08